Antapodia Therapeutics uses the market's most advanced 3rd-generation lipid nanoparticle (3gLNPs) platform to deliver Master Invadopodial Regulator (MIR)-targeted small interfering RNAs (siRNAs) to invasive cancer cells to inhibit their invadopodia formation (Figure 1). The company's first-in-class anti-invadopodia cancer gene therapy, AP-01, specifically targets MIR-01 to inhibit invadopodial biogenesis, thereby halting cancer spreading and metastasis. Antapodia Therapeutics also developed a first-in-class invadopodia-targeted monoclonal antibody AP-03, which specifically blocks the invadopodia-surface protein MIR-03. The company has completed a series of POM and POC studies to demonstrate the remarkable anti-tumor and anti-metastasis efficacy of these novel and powerful invadopodia-targeted anti-cancer therapeutics.


Product (Target Diseases)

AP-01 3gLNP-siRNA

(HCC, TNBC, undisclosed)

Target gene/Companion Dx



PoM/PoC studies > In vitro testing > In vivo testing > Toxicity > IND enabling

Product (Target Diseases)

AP-03 mAb


Target Gene



PoM/PoC studies > In vitro testing > In vivo testing > Toxicity > IND enabling

3gLNP: third-generation lipid nanoparticle; MIR: Master Invadopodial Regulators; siRNA: small interfering RNA; HCC: hepatocellular carcinoma; TNBC: triple-negative breast cancer; SCLC: small cell lung cancer; NSCLC: non-small cell lung cancer; mAb: monoclonal antibody.

Figure 1. The mechanisms of action of Antapodia's invadopodia-targeted siRNA therapy AP-01


AP-01 is fabricated by formulating MIR-01-targeted chemically modified siRNAs (cm-siRNAs) using the 3rd-generation lipid nanoparticles (3gLNPs). When delivered to tumors through intravenous (IV) or intratumoral (IT) injections, the loaded LNP diffuses into tumors through the enhanced permeability and retention (EPR) effect, which is then internalized by cancer cells followed by the release of the siRNAs, thereby inhibiting the expression of MIR-01 and crippling invadopodial biogenesis and cancer cell invasiveness. The combined administration of liver-blocking liposomes can “mask” Kupffer cells in the liver, enhancing the bioavailability of these LNP gene-therapeutics in non-liver and metastatic cancers


Designed by Justin V. Tsai in 2021

Copyright © Antapodia Therapeutics, Inc., WA, USA. All Rights Reserved.